Latest findings released, for the first time, show sustained myopia control efficacy of the lens in children, saving more than one and a quarter dioptres of myopia over four years. Four–year data follows the recent publication of the three–year clinical trial findings in American Journal of Ophthalmology, which also highlights evidence of continued myopia control efficacy of the lens
The clinical trial which began in 2018 was conducted at the Eye Hospital of Wenzhou Medical University in Wenzhou, China. The study assessed the four–year increase of myopia and axial eye length of children who wore spectacle lenses with highly aspherical lenslets (HAL). Essilor Stellest lenses are based on the optical design of HAL lenses.
– Myopia progression and axial eye elongation in children wearing HAL lenses was slower compared to a
modelled control single vision lens group, again indicating sustained myopia control efficacy of the lenses in the fourth year.
– HAL lenses remain effective in slowing myopia progression and axial eye elongation in older children (11–16 y.o.) in the fourth year.
time was similar or slower than that of non–myopic children, after two years. The release of the four–year data follows the recent publication of the three–year clinical trial findings in the medical journal American Journal of Ophthalmology, which also highlights evidence of continued myopia control efficacy of the
lens in slowing down myopia progression in children over three years.
Norbert Gorny, co–Chief Operating Officer at EssilorLuxottica, said, “We are proud to share the latest findings from our four–year study of the Essilor Stellest lens at ARVO, which demonstrate that the myopia control effect of the lens is sustainable over four years. We look forward to sharing additional data with the scientific community. Such encouraging, evidence–based findings will significantly help to enhance scientific understanding and clinical interest for myopia control solutions like the Essilor Stellest lens globally. To move the needle further, we will continue to advance myopia research, deliver innovative solutions, build partnerships to strengthen awareness and education, share insights and expertise at key conferences, and much more.”